41 results about "Cancer imaging" patented technology

The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.

Methods are provided for cancer and pre-cancer detection by increased uptake of fluorophore glucose or deoxyglucose conjugates in cancerous and pre-cancerous cells relative to normal cells.

The invention relates to an amphiphilic illuminant with aggregation induced emission characteristics and applications thereof. The illuminant is prepared by connecting a hydrophilia unit on a classical hydrophobicity unit of the classical aggregation induced emission characteristics (AIE), and can be applied to a fluorescent light chemical sensor and is used for preparing fluorescent light coloring agent which is used for coloring living cells and animal imaging fluorescent light. The amphiphilic coloring agent is specifically suitable for the fluorescent light mark on biopolymer, and can be used as a biocompatibility probe for AIE activation so that the amphiphilic coloring agent can be applied to clinic cancer imaging, diagnose and treatment.

The invention provides modified gold nanoparticles that enable a non-invasive, real time, targeted cancer imaging-therapeutic in one step. After reaching the cancer targets, the designed targeted gold nanoparticles significantly enhance conventional treatment modalities at the cellular level. In this aspect the gold nanoparticles of the invention are modified to be bound to a Positron Emission Tomography (PET) tracer.

Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided.

The invention discloses a door control type medicine composition integrating cancer imaging and phototherapy and a preparation method. The preparation method comprises the following steps: (1) preparing CuS@mSiO2 nano particles in a core-shell structure; (2) preparing ammoniated CuS@mSiO2 nano particles; and (3) preparing CuS@mSiO2-TD/ICG. Each CuS@mSiO2 nano particle in the core-shell structure, prepared in the invention, is provided with a silicon dioxide shell with a suitable thickness, so that the common load of indocyanine green and TD can be guaranteed; the CuS@mSiO2-TD/ICG can well play a preferable door control role, and the release of indocyanine green is controlled; and during systemic circulation, the effect of opto-thermodynamics and photodynamics combination therapy is achieved. The door control type medicine composition has good water solubility and biocompatibility. The therapeutic effect of tumors can be effectively strengthened, and the toxic and side effects are reduced. The preparation technology is simple, the method is stable and reliable, the reaction controllability is high, and the used raw materials are easily obtained and are low in cost.

The invention discloses a protein-dye complex and an application thereof. The protein-dye complex comprises human serum albumin and a heptamethine Indocyanine derivative, wherein human serum albumin is used as a carrier, the heptamethine cyanine derivative is adsorbed on the carrier via hydrophobic interaction; the molar ratio of human serum albumin to the heptamethine cyanine derivative is 1:1; the human serum albumin has a molecular weight of 69 KDa; the heptamethine cyanine derivative has a molecular weight of 983.5 Da; and the protein-dye complex has a particle size of 8-10 nanometers. The nanoparticle has high optical absorption property in near-infrared region and strong fluorescence in visible light region, has good dispersibility, and can be used for preparing cancer imaging diagnosis and treatment preparations.

The invention discloses an intermediate-advanced stage cancer imaging detecting system and an intermediate-advanced stage cancer imaging detecting method based on the quantum superstring engine, mainly used for overcoming the defect that the traditional medical device can not efficiently, safely, rapidly and comprehensively detect the cancer cell spreading area of a cancer patient. The intermediate-advanced stage cancer imaging detecting system comprises a quantum light emission source, an optical splitter, a convex lens, a light filter group, a detection unit, an image processing unit and a display. The intermediate-advanced stage cancer imaging detecting method comprises the steps that orthogonal polarized photons generated by the quantum light emission source pass through the optical splitter, and then are transmitted in two paths; one path of the orthogonal polarized photons irradiates the body of the patient through the convex lens and light filters, penetrates through the body and then is received by a detector, and the other path of the orthogonal polarized photons directly passes through the light filters, and are received by another detector; the detection unit carries out combined measurement on the photons detected by the two detectors, and outputs a detection result to the image processing unit, the image processing unit draws a diffusion area imaging picture of cancer cells in the body of the patient, and the diffusion area imaging picture is displayed by the display. With the adoption of the intermediate-advanced stage cancer imaging detecting system and the intermediate-advanced stage cancer imaging detecting method, the diffusion area imaging picture of the cancer cells can be obtained, and thus a basis is provided for the treatment and research on the cancer patient.

Embodiments of the present invention relates to compounds of the following formula:

as well as compositions, methods of imaging and methods of treating subjects comprising the use of the compound, wherein the variables are defined herein.

The invention provides a novel multi-modal fusion auxiliary diagnosis method based on rectal cancer imaging omics research. The method comprises the following steps of: 1, acquiring medical images ofmultiple modes of rectal cancer, and preprocessing the medical images; 2, segmenting the preprocessed medical image into layers, and obtaining a region of interest corresponding to each layer of medical image; 3, performing feature extraction on each region of interest of each modal medical image, so that corresponding high-dimensional image omics features can be obtained; 4, randomly dividing theobtained samples and correspondingly obtained high-dimensional image omics features to obtain a training set and a test set, and performing feature dimension reduction in training group data; 5, respectively constructing image omics labels based on T2 weighted imaging, diffusion weighted imaging and low-dimensional image omics characteristics of the CT image; and 6, carrying out coefficient weighting on each obtained label, and carrying out linear combination to obtain a multi-modal fusion imaging omics score for rectal cancer auxiliary diagnosis.

The invention comprises a fiducial marker—fiducial detector based treatment room position determination/positioning system apparatus and method of use thereof. A set of fiducial markers and fiducial detectors are used to mark/determine relative position of static and/or moveable objects in a treatment room using photons passing from the markers to the detectors. Further, position and orientation of at least one of the objects is calibrated to a reference line, such as a zero-offset beam treatment line passing through an exit nozzle, which yields a relative position of each fiducially marked object in the treatment room. Treatment calculations are subsequently determined using the reference line and/or points thereon. The treatment calculations are optionally and preferably performed without use of an isocenter point, such as a central point about which a treatment room gantry rotates, which eliminates mechanical errors associated with the isocenter point being an isocenter volume in practice.

The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR) and to its use in a method of labelling and/or detecting and/or treating cancerous cells in a subject by administration of the conjugated compound to the subject an analysis of the presence and/or the amount of marker.